[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR022254A1 - Composicion de administracion oral. - Google Patents

Composicion de administracion oral.

Info

Publication number
AR022254A1
AR022254A1 ARP000100111A ARP000100111A AR022254A1 AR 022254 A1 AR022254 A1 AR 022254A1 AR P000100111 A ARP000100111 A AR P000100111A AR P000100111 A ARP000100111 A AR P000100111A AR 022254 A1 AR022254 A1 AR 022254A1
Authority
AR
Argentina
Prior art keywords
oral administration
administration composition
composition
microns
granulometry
Prior art date
Application number
ARP000100111A
Other languages
English (en)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR022254A1 publication Critical patent/AR022254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composicion de administracion oral con liberacion controlada de un analgésico opioide en forma de cristales con una granulometría de 10 micrones hasta 3mm,preferiblemente 50 micrones hasta 3mm, que presentan al menos un revestimiento retardante.
ARP000100111A 1999-01-18 2000-01-11 Composicion de administracion oral. AR022254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901687A DE19901687B4 (de) 1999-01-18 1999-01-18 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
AR022254A1 true AR022254A1 (es) 2002-09-04

Family

ID=7894566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100111A AR022254A1 (es) 1999-01-18 2000-01-11 Composicion de administracion oral.

Country Status (24)

Country Link
US (1) US6685964B1 (es)
EP (1) EP1020185B1 (es)
JP (1) JP2000212072A (es)
KR (1) KR20000071247A (es)
CN (1) CN1244327C (es)
AR (1) AR022254A1 (es)
AT (1) ATE257012T1 (es)
AU (1) AU771064B2 (es)
CA (1) CA2295471A1 (es)
CO (1) CO5251462A1 (es)
DE (2) DE19901687B4 (es)
DK (1) DK1020185T3 (es)
ES (1) ES2213971T3 (es)
HK (1) HK1029749A1 (es)
HU (1) HUP0000138A3 (es)
IL (1) IL134076A (es)
NZ (1) NZ502261A (es)
PE (1) PE20001395A1 (es)
PL (1) PL337867A1 (es)
PT (1) PT1020185E (es)
RU (1) RU2239417C2 (es)
SI (1) SI1020185T1 (es)
SK (1) SK285129B6 (es)
ZA (1) ZA200000173B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
ATE274906T1 (de) * 2000-09-22 2004-09-15 Smb Technology Oral anzuwendende tramadolhaltige teilchen zur einmal täglichen verabreichung
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
ATE345112T1 (de) * 2001-05-11 2006-12-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1476155A4 (en) * 2002-01-23 2009-10-28 Univ California METHODS AND COMPOSITIONS FOR REDUCING THE DEVELOPMENT OF DRUG TOLERANCE AND / OR PHYSICAL DEPENDENCE
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
ATE386509T1 (de) * 2002-09-21 2008-03-15 Shuyi Zhang Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
CN100336501C (zh) * 2003-08-06 2007-09-12 健乔信元医药生技股份有限公司 醋炎痛缓释性圆粒组成物及制备方法
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
EP1754471A1 (de) * 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
EA014739B1 (ru) 2005-09-09 2011-02-28 Лабофарм Инк. Композиция тразодона для введения один раз в день
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
BRPI0708640A8 (pt) * 2006-03-06 2018-04-24 Pozen Inc composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
GB0625646D0 (en) * 2006-12-21 2007-01-31 Jagotec Ag Improvements in or relating to organic compounds
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
GB0714790D0 (en) * 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
CN102209529A (zh) 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
DK3045043T3 (da) * 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
KR20120093140A (ko) * 2009-06-25 2012-08-22 포젠 인크. 아스피린 치료를 필요로 하는 환자의 치료 방법
CN102481293A (zh) 2009-06-25 2012-05-30 阿斯利康(瑞典)有限公司 治疗具有发展nsaid-相关的溃疡的风险的患者的方法
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
MX362838B (es) 2012-07-12 2019-02-19 SpecGx LLC Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CN106176683B (zh) * 2016-08-31 2019-04-16 贵州益康制药有限公司 一种盐酸曲马多缓释胶囊及其制备方法和用途
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2024193475A1 (zh) * 2023-03-17 2024-09-26 浙江大学 一种控释制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
EP0153105B1 (en) * 1984-02-10 1992-09-09 Benzon Pharma A/S Diffusion coated multiple-units dosage form
US5095151A (en) * 1985-05-21 1992-03-10 American Home Products Corporation Preparation of propranolol hydrochloride macrocrystals
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
EP1442745A1 (en) 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
DE69429710T2 (de) * 1993-11-23 2002-08-08 Euro-Celtique S.A., Luxemburg/Luxembourg Verfahren zur Herstellung einer Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung

Also Published As

Publication number Publication date
ZA200000173B (en) 2000-08-07
CN1270029A (zh) 2000-10-18
IL134076A (en) 2005-05-17
CA2295471A1 (en) 2000-07-18
ES2213971T3 (es) 2004-09-01
NZ502261A (en) 2001-11-30
PE20001395A1 (es) 2000-12-23
SI1020185T1 (en) 2004-04-30
DK1020185T3 (da) 2004-02-16
HUP0000138A3 (en) 2001-03-28
AU771064B2 (en) 2004-03-11
CO5251462A1 (es) 2003-02-28
HK1029749A1 (en) 2001-04-12
DE19901687A1 (de) 2000-07-20
HUP0000138A2 (hu) 2001-02-28
HU0000138D0 (en) 2000-03-28
SK285129B6 (sk) 2006-07-07
PT1020185E (pt) 2004-05-31
ATE257012T1 (de) 2004-01-15
US6685964B1 (en) 2004-02-03
DE59908195D1 (de) 2004-02-05
JP2000212072A (ja) 2000-08-02
SK642000A3 (en) 2000-08-14
AU1011300A (en) 2000-07-20
RU2239417C2 (ru) 2004-11-10
CN1244327C (zh) 2006-03-08
KR20000071247A (ko) 2000-11-25
EP1020185A2 (de) 2000-07-19
EP1020185B1 (de) 2004-01-02
IL134076A0 (en) 2001-04-30
DE19901687B4 (de) 2006-06-01
EP1020185A3 (de) 2000-09-27
PL337867A1 (en) 2000-07-31

Similar Documents

Publication Publication Date Title
AR022254A1 (es) Composicion de administracion oral.
NO20020208L (no) Flytende sammensetninger for oral administrasjon
PT1110543E (pt) Composicao de libertacao prolongada para administracao oral
HUP0401714A3 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
BR0115382A (pt) Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
ZA200007715B (en) Stable extended release oral dosage composition.
DE69941115D1 (de) Tablette mit einzelnem kern zur oralen verabreichung mit kontrollierter freisetzung
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
DE69942928D1 (de) Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
SE9704870D0 (sv) New pharmaceutical formulation I
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
DE60043447D1 (de) Zusammensetzungen mit kontrollierter freigabe enthaltend nimesulid
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
NO20000284D0 (no) Tanninsyre-polymerblandinger for kontrollert frigivelse av farmasoeytiske midler, saerlig i munnhulen
NO20014738L (no) Tolperisonholdig farmasöytisk preparat for oral administrering
PL347105A1 (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
AU2002222750A1 (en) Pharmaceutical composition for intramuscular injection containing loxoprofen
AU1712700A (en) Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
ECSP003316A (es) Composicion de administracion oral con liberacion controlada de un analgesico opioide en forma de cristales
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
ECSP003508A (es) Formas polimorfas de un citrato de azobiciclo [2.2.2] octan-3-amina y sus composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure